Previous 10 | Next 10 |
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020. For the second quarter of 2020, worldwide sales from continuing operations were $182.2 million, a decrease of 34.3 percent on a reported basi...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials 1 , which details the design for “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem o nstrating the Safet...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m. London time (7 a.m. Eastern Daylight Time). The Company will release its second quarter 2020 re...
This article part of a series that provides an ongoing analysis of the changes made to Harris Associates' 13F stock portfolio on a quarterly basis. It is based on Harris Associates' regulatory 13F Form filed on 05/15/2020. William Nygren's 13F portfolio value decreased ~36% from $56.41B to $...
LivaNova ( LIVN -0.6% ) has priced private offering of $250M cash exchangeable senior notes due 2025, at 3.00% p.a., interest payable semi-annually. More news on: LivaNova PLC, Read more ...
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S. subsidiary, LivaNova USA, Inc., in a private offering to qualified institutional ...
LivaNova PLC (NASDAQ:LIVN) ("LivaNova") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S. subsidiary, LivaNova USA, Inc., in a private offering to qualified institutional buyers pursuant to R...
LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S. subsidiary, LivaNova USA, Inc. with funds managed by ...
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern Time. The discussion will be available to all interested partie...
PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus Standard-Aortic Valve ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...
2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...